3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Dermatologic
1
Conditions
Sarcoma
1
Liposarcoma
1
Leiomyosarcoma
1
Hemangiosarcoma
1
Dermatofibrosarcoma
1
Interventions
Temozolomide
63
Cyclophosphamide
55
Radiotherapy
53
Bevacizumab
50
Doxorubicin
48
Ifosfamide
33
pazopanib
28
fludarabine phosphate
28
Etoposide
27
Radiation
24
Gemcitabine
24
pembrolizumab
23
Sirolimus
23
Sunitinib
22
Filgrastim
22
Irinotecan
21
Whole-Body Irradiation
20
Peripheral Blood Stem Cell Transplantation
20
Mycophenolic Acid
20
Imatinib Mesylate
20
Vincristine
19
Magnetic Resonance Spectroscopy
18
Sorafenib
16
Methotrexate
16
Busulfan
16
Melphalan
15
Carboplatin
15
Docetaxel
14
Cyclosporine
14
temsirolimus
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
TTI-621
×
Sarcoma
×
Clear all
NCT04996004
2024-12-11
TTI-621-03
Pfizer
Phase 2
Terminated
76 enrolled
53 charts